Skip to main content

MECHANISMS OF ER-POSITIVE BREAST CANCER METASTASIS

SAF2010-21171

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation

  • Morales, Mònica
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Urosevic, Jelena
  • Guiu, Marc|||0000-0002-7083-986X
  • Fernández Mostaza, Esther|||0000-0002-2335-0674
  • Planet, Evarist
  • Fenwick, Robert Bryn
  • Fernández Ruiz, Sonia
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Massagué, Joan
  • Gomis, Roger R.|||0000-0001-6473-2858
In estrogen receptor-negative breast cancer patients, metastatic relapse usually occurs in the lung and is responsible for the fatal outcome of the disease. Thus, a better understanding of the biology of metastasis is needed. In particular, biomarkers to identify patients that are at risk of lung metastasis could open the avenue for new therapeutic opportunities. Here we characterize the biological activity of RARRES3, a new metastasis suppressor gene whose reduced expression in the primary breast tumors identifies a subgroup of patients more likely to develop lung metastasis. We show that RARRES3 downregulation engages metastasis-initiating capabilities by facilitating adhesion of the tumor cells to the lung parenchyma. In addition, impaired tumor cell differentiation due to the loss of RARRES3 phospholipase A1/A2 activity also contributes to lung metastasis. Our results establish RARRES3 downregulation as a potential biomarker to identify patients at high risk of lung metastasis who might benefit from a differentiation treatment in the adjuvant programme.